Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Division of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Ann Surg Oncol. 2024 Nov;31(12):8308-8316. doi: 10.1245/s10434-024-15934-1. Epub 2024 Aug 2.
Ampulla of Vater carcinoma (AVC) stage T3 was subdivided according to the degree of pancreatic invasion into T3a (≤ 0.5 cm) and T3b (> 0.5 cm) by the 8th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) cancer staging system. However, the differences in clinicopathological features and survival outcomes between the two categories have not been well discussed.
We retrospectively analyzed 133 consecutive patients who underwent pancreatoduodenectomy for AVC at our institution between 2002 and 2020. Clinicopathological features and survival outcomes of patients with AVC were analyzed, with a focus on the depth of pancreatic invasion. In addition, the survival outcomes of patients with T3 AVC were compared with those of patients with resectable pancreatic head carcinoma (R-PhC) who underwent pancreatoduodenectomy during the same period.
The overall survival (OS) in patients with T3b AVC (n = 12) was significantly worse than that in patients with T3a AVC (n = 39) [median survival time (MST) 9.2 vs. 74.5 months, p < 0.001). A multivariate analysis identified T3b tumor (hazard ratio 5.64, p = 0.009) as an independent prognostic factor. The OS of patients with T3a AVC was significantly better than that of patients with R-PhC who received adjuvant chemotherapy (n = 276, MST 35.0 months, p = 0.007). In contrast, the OS of patients with T3b AVC tended to be worse than that of patients with R-PhC managed without adjuvant chemotherapy, although this difference was not statistically significant (n = 163; MST, 17.5; p = 0.140).
AVC with > 0.5 cm invasion into the pancreas was associated with poor survival and represented advanced tumor progression to systemic disease.
第 8 版国际癌症控制联盟(UICC)/美国癌症联合委员会(AJCC)癌症分期系统根据胰腺侵犯程度将 Vater 壶腹癌(AVC)T3 期进一步分为 T3a(≤0.5cm)和 T3b(>0.5cm)。然而,这两类之间的临床病理特征和生存结局差异尚未得到充分讨论。
我们回顾性分析了 2002 年至 2020 年期间在我院接受胰十二指肠切除术治疗 Vater 壶腹癌的 133 例连续患者。分析 Vater 壶腹癌患者的临床病理特征和生存结局,重点关注胰腺侵犯深度。此外,还比较了 T3 AVC 患者的生存结局与同期接受胰十二指肠切除术的可切除胰头癌(R-PhC)患者的生存结局。
T3b AVC(n=12)患者的总生存(OS)明显差于 T3a AVC(n=39)患者[中位生存时间(MST)9.2 与 74.5 个月,p<0.001]。多因素分析显示 T3b 肿瘤(危险比 5.64,p=0.009)是独立的预后因素。T3a AVC 患者的 OS 明显优于接受辅助化疗的 R-PhC 患者(n=276,MST 35.0 个月,p=0.007)。相比之下,T3b AVC 患者的 OS 似乎比未接受辅助化疗的 R-PhC 患者差,尽管差异无统计学意义(n=163;MST 17.5;p=0.140)。
0.5cm 胰腺侵犯的 Vater 壶腹癌与生存不良相关,代表了全身性疾病的肿瘤进展。